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Community-acquired pneumonia (CAP) exhibits mortality rates, between 20% and 50% in severe cases. Biomarkers
are useful tools for searching for antibiotic therapy modifications and for CAP diagnosis, prognosis and follow-up
treatment. This non-systematic state-of-the-art review presents the biological and clinical features of biomarkers in
CAP patients, including procalcitonin, C-reactive protein, copeptin, pro-ANP (atrial natriuretic peptide),
adrenomedullin, cortisol and D-dimers.
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INTRODUCTION
Approximately 4 million adults develop community-
acquired pneumonia (CAP) in the United States (U.S.)
annually; CAP is also the eighth leading cause of death in
the U.S. (1). Severe CAP is responsible for 6.6% to 16.7% of
pneumonia hospitalizations in Europe and the U.S. (2,3).
The highest mortality rates, between 20% and 50%, are
observed in severe CAP infections in Spanish and British
intensive care units (ICUs) (4,5).
Hospitalized CAP patients undergo clinical, radiological
and laboratory tests to determine the disease severity,
need for ICU hospitalization and possible complications.
Hemograms, urea, creatinine, glucose, hepatic function tests,
pulse oximetry, arterial blood gasometry and blood and
sputum cultures are critically important (6,7). Identifying the
etiological agent has no relevant effect on the hospitalization
time or mortality in the first 30 days or between the
comparisons of focused therapy and the identified agent or
empirical therapy across a large spectrum (8).
Severity scores, such as the Pneumonia Severity Index (PSI)
and CURB-65 (confusion, urea, respiratory rate, arterial
blood pressure and age) scores, have been developed and
validated. These scores can aid the decision-making process
of hospitalization and ICU referral (9).
Biomarkers are useful tools in the diagnosis, prognostics
and follow-up treatment of CAP and for investigating
antibiotic modifications. This article presents a non-sys-
tematic, state-of-the-art review of the biological and clinical
features of CAP biomarkers.
Procalcitonin
Procalcitonin (PCT) is a protein that is encoded by the
CALC-I gene on chromosome 11, which produces calcitonin
and several additional free peptides after several post-
translational modifications (10).
PCT concentrations in the serum of healthy subjects are
undetectable or low, generally ,0.1 ng/mL (11). PCT is
detected in other tissues in healthy subjects, but the
transcription of the extra-thyroid CALC-I gene is poor in
the absence of infection. PCT mRNA is up-regulated in
sepsis, which increases the expression and secretion of this
peptide in tissue (10).
Inflammatory and infectious injuries stimulate the
increase in serum PCT (11). The synthesis of this peptide is
particularly induced during severe bacterial infection, sepsis,
septic shock and multiple organ dysfunction syndrome (12).
PCT supports a CAP diagnosis, and this protein is a
predictor of complications and mortality. PCT and C-reactive
protein (CRP) enhance the diagnostic accuracy of the clinical
signs and symptoms that are routinely used for screening
and diagnosing CAP (13). The standard clinical model
exhibited a diagnosis accuracy of 0.79 (IC 95% 0.75–0.83) in
this study, and including these biomarkers increased the
accuracy to 0.92 (IC 95% 0.89–0.94), which was significantly
better than the association of one of these biomarkers alone
(p,0.001 for both comparisons).
Boussekey et al. (11) have also evaluated the prognostic
value of PCT for CAP and demonstrated that PCT.2 ng/mL
was associated with an increased incidence of bacteremia,
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septic shock, multi-organ failure and mortality. No associa-
tion for CRP was observed. Antibiotic administration must be
based on the PCT cutoff ranges (14). Antibiotic treatment is
intensified when the infection is severe and the PCT levels
remain elevated (.0.25 or 0.5 ng/L). Antibiotics may be
discontinued when the PCT levels decrease rapidly.
Christ-Crain et al. (15) demonstrated that using PCT for
therapeutic guidance substantially reduced total antibiotic
exposure and decreased the treatment duration by 55%
compared to the standard therapeutic treatment (median 12
days vs. 5 days, p,0.001). Reduced adverse effects and
microbiological resistance rates and shortened antibiotic
therapy courses improve resource allocations, which is an
important factor in public healthcare.
C-Reactive Protein
C-reactive protein (CRP) was the first ‘‘acute phase’’
protein to be described (16). CRP was discovered in the
serum of patients with pneumococcal pneumonia; the CRP
precipitated at the C-polysaccharides from the bacterial
membrane. Combining CRP with the phosphocholine
molecule responded to C-polysaccharide and other bacterial
and host cell membrane constituents. Other ligands have
also been described.
CRP activates the classical complement pathway, stimu-
lates phagocytosis, binds to the immunoglobulin receptors,
and interacts with several molecules (17). CRP values
,3 mg/L are normal, and values.10 mg/L indicate sig-
nificant inflammation (18). CRP is a sensitive inflammatory
biomarker, but it exhibits low specificity. CRP values
between 3 mg/L and 10 mg/L may reflect numerous
conditions, such as obesity, smoking, diabetes mellitus,
uremia, hypertension, low physical activity, oral hormone
replacement therapy, sleep disturbances, chronic fatigue,
alcohol consumption, depression, aging and other states that
do not necessarily include inflammation (19).
A cut-off point of 11 mg/L serum CPR demonstrated a
94% sensitivity and 95% specificity in healthy individuals
and CRP patients, respectively. These data suggest that CPR
values below this point may exclude a confirmed CAP
diagnosis. With an 83% sensitivity and 44% specificity, a
cut-off point of 33 mg/L CRP distinguished the patients
with a confirmed CAP diagnosis from the patients with
similar clinical symptoms but different clinical conditions
(20).
Chalmers et al. (21) concluded that CRP values,100 mg/
L in CAP patients on the day of admission and four days
later were independently associated with a low 30-day
mortality rate, low probability for mechanical ventilation
and/or inotropic support and low rates of complicated
pneumonia. The risks of 30-day mortality, need for mechan-
ical ventilation and/or inotropic support and complicated
pneumonia increased when the CPR levels did not drop by at
least 50% until the fourth day of admission.
A cohort of 53 subjects (22) demonstrated that daily
measurements of serum CRP in the patients with severe
CAP are useful for identifying the patients with a poor
prognosis, and this biomarker is a better predictor than the
commonly used markers of infection, such as body
temperature and leukocyte count. This study also demon-
strated that shorter antibiotic therapy might exhibit the
same efficacy with less toxicity in patients with a rapid drop
in CRP levels, thereby avoiding the emergencies that are
associated with resistant strains and reducing hospitaliza-
tion costs.
Copeptin
Arginine-vasopressin (AVP) is a hormone that is pro-
duced in the paraventricular nuclei of the hypothalamus
and stored in the posterior part of the pituitary gland.
Several stimuli, such as hypotension, hypoxia, hyperosmo-
larity, acidosis and infections, stimulate the release of AVP
(23). AVP is released into the circulatory system by osmotic
and hemodynamic stimuli. AVP exerts antidiuretic and
vasopressor effects, which may restore the vascular tonus in
vasodilatation hypotension (24).
Copeptin is a 39-amino acid glycopeptide, and its
physiological function is unknown. AVP and neurophysin
II comprise the terminal portion of the pre-pro-vasopressin
molecule (25). Copeptin may play an important role in the
correct structural formation of the AVP precursor, which is
required for its proteolytic maturation efficiency (26).
Serum AVP levels have limitations because of the short
half-life of AVP and its molecular instability. However,
copeptin is highly stable ex vivo even for several days at
room temperature. Ex vivo copeptin may be an indirect
parameter to estimate the AVP plasma concentrations in
critical patients, including the patients with sepsis and
septic shock, for whom the levels of these biomarkers are
high (27,28).
The presence of copeptin indicates the need for follow-up
treatment for different types of pneumonia. Copeptin may
be an independent predictor of mortality in CAP. CAP was
an independent predictor of mortality in ventilation-
associated pneumonia, and mortality rates increased with
the severity of the sepsis (29).
Pro-ANP
Members of the family of natriuretic peptides are
established biomarkers for congestive heart failure (30).
These proteins defend the body against hypertension and
salt and water retention by antagonizing the renin-angio-
tensin-aldosterone system. Natriuretic proteins alter renal
sodium reabsorption, vascular tonus and cell growth. The
smooth muscles of the blood vessels and kidneys are the
primary targets of atrial natriuretic peptide (ANP). ANP
distends the smooth muscles of the vessels, and increases
the permeability of capillaries, which facilitates the removal
of water and sodium. This hormone also inhibits the
function of several other hormones, such as endothelin
and vasopressin (31).
ANP is predominantly produced in the atrium of the heart,
and this peptide comprises 98% of the natriuretic peptides in
circulation. The pre-pro-ANP hormone is composed of 151
amino acids. The amino acid chain is called pro-ANP after
removing a 25-amino acids signal sequence. The pro-ANP is
likely cleaved by the membrane proteins in a functional ANP
chain to a 28-amino acid peptide and an amino-terminal
fragment of 98 amino acids (the NT-pro-ANP) prior to
exocytosis (32).
Distended atrial walls signal the ANP release. High
cardiac output, sympathetic stimulation and metabolic
factors influence the ANP release. It is also suspected that
hypoxia influences the ANP release. The half-life of ANP is 2
to 5 minutes, and its degradation rate is approximately 14 to
25 mL/min/kg (33).
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ANP is a marker for the prevention and differential
diagnosis of several diseases. The use of this peptide in
diagnosing dyspnea caused by heart failure is more efficient
than traditional methods (34). ANP and pro-ANP are
interesting new sepsis and pneumonia markers (35,36).
Morgenthaler et al. (37) have compared the pro-ANP levels
to the APACHE II score (Acute Physiology and Chronic
Health Evaluation) as an outcome predictor in septic
patients.
Adrenomedullin
Human adrenomedullin (ADM) is a 52-amino acid
peptide that is synthesized as part of pre-pro-adrenome-
dullin, a larger precursor molecule (38). The ADM gene is
expressed in a wide range of tissues, but initial studies on
the distribution of this gene have suggested that the highest
levels of expression are observed in the adrenal medulla,
ventricular chambers, kidneys and lungs (39). The ADM
gene is more highly expressed in the endothelial cells than
the adrenal medulla, and this peptide is a secretory product
of the vascular endothelium, which also includes nitric
oxide (NO) and endothelin (40).
The plasma half-life of ADM is approximately 22 minutes
(41). The normal plasma concentrations of ADM range from
1 to 10 ng/mL, and most values are between 2 and 3.5 ng/
mL (42). However, obtaining reliable measurements of
ADM release in blood circulation is difficult because ADM
immediately binds to receptors near the site of its produc-
tion. The short half-life of ADM and technical difficulties
also complicate the plasma measurements (43).
The plasma ADM levels are elevated in a wide range of
disease states, usually as a compensatory response to
cardiovascular disturbances (42). ADM likely participates
in the physiopathology of septic shock because this is the
only pathological condition in which the plasma levels of
this protein approach the levels that are required for
receptor activation. The ADM plasma levels in sepsis
patients are directly responsible for hypotension during
septic shock (44).
Christ-Crain et al. (45) have noted that the levels of MR-
pro-ADM on admission increased according to the CAP
severity (based on the PSI score). MR-pro-ADM is a stable,
functionally irrelevant fragment of ADM degradation that is
used in some studies because of its better technical viability.
This progressive increase was also observed in procalcitonin
(p,0.0001). However, no statistical significance was
observed for the C-reactive protein, total leukocyte count,
and body temperature.
The ADM levels upon admission were significantly
higher in the patients who died during the follow-up
compared to the patients who survived: 2.1 (1.5–3.0 nmol/
L) vs. 1.0 (0.6–1.6 nmol/L) (p,0.001). An analysis of the
‘‘treatment failure’’ and ‘‘death’’ outcomes demonstrated
that the prognostic accuracy of ADM was similar to the PSI
score but higher than other parameters (44).
Kru¨ger et al. have demonstrated that the MR-proANP
(mid-regional pro-atrial natriuretic peptide), copeptin, CT-
proET-1 (proendothelin-1), and MR-proADM (mid-regional
proadrenomedullin) biomarkers are strong predictors of the
28- and 180-day CAP mortality, and MR-proADM exhibited
the best performance. The combination of CRB-65 and MR-
proADM was the best predictor for short- and long-term
mortality (46).
Cortisol
The hypothalamic-pituitary-adrenal circuit is activated by
central stress control circuits to produce and secrete the
corticotropin-releasing hormone (CRH). CRH stimulates the
anterior portion of the pituitary gland to synthesize and
release proopiomelanocortin (POMC), an adrenocorticotro-
pin (ACTH) precursor. In the systemic circulation, ACTH
activates the transcription of steroids, particularly cortisol,
in the adrenal gland (47).
Cortisol secretion increases in amplitude but not fre-
quency after three to five hours of sleep, and secretion peaks
a few hours before waking until one hour after waking.
Cortisol amplitude decreases in the morning and reaches a
minimum level at dawn (48). The half-life of cortisol is
approximately 80 minutes, which is longer than the 8-
minute half-life of ACTH (49). The plasma cortisol levels are
higher in cases of severe trauma, burns, major surgery,
hypoglycemia, fever, blood pressure changes, exercise and
exposure to intense cold (50-53).
Salluh et al. have demonstrated that treatment with
supraphysiological doses of hydrocortisone increases the
survival rates of severe CAP patients who develop adrenal
failure during septic shock (54). A study of 72 CAP patients
demonstrated that the baseline level of total cortisol was
significantly higher in non-survivors. These results confirm
the interference of infection in adrenal functions and
support the value of cortisol as a better predictor of
mortality compared to severity-related scores (APACHE II,
CURB-65, SOFA) and laboratory markers (CRP, leukocyte
count, and d-dimers) (55).
D-dimers
D-dimers are released into the blood during the dissolu-
tion process of fibrin emboli in the fibrinolytic system. D-
dimers are the smallest fragments of the fibrin degradation,
and these proteins are detectable in blood plasma. The half-
life of this protein is approximately 8 hours, and it is cleared
from the plasma via urinary excretion and the action of the
reticuloendothelial system (56).
High d-dimers levels have been detected in patients with
disseminated intravascular coagulation (DIC), severe sepsis,
thrombotic events, hepatic diseases, surgery and trauma
(57-59). The most important application of d-dimers is
related to thrombotic events. D-dimers have been studied
extensively as a diagnostic method for deep vein thrombosis
(DVT) and pulmonary embolism (PE). A negative result has
diagnostic utility that is comparable to normal lung scans or
negative duplex ultrasound findings (60).
The application of the d-dimers analysis to CAP is a novel
approach. In a cohort study of 68 CAP patients, Shilon et al.
have demonstrated a positive correlation between d-dimers
and PSI, APACHE II, hospitalization time, organ failure,
fever duration, and hospital mortality (61). Another study of
302 CAP patients (62) investigated the relationships
between plasma d-dimers levels and the prognostic vari-
ables that are included in the PSI. High d-dimers levels were
associated with radiological pneumonia extension findings.
Using biomarkers may aid in the diagnosis, treatment
and prognosis of CAP. Table 1 summarizes the reviewed
biomarkers and triggers. The PCT serum levels may provide
valuable support to the clinical diagnosis of CAP and aid in
the differential diagnosis of bacterial and viral pneumonia.
PCT is particularly useful because the results are obtained
several days prior to the culture tests. These biomarkers also
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aid in identifying the low-risk patients who can be treated in
outpatient environments. Reducing unnecessary hospitali-
zations decreases treatment costs and patient discomfort.
Protocols based on PCT levels can substantially reduce
the use of antibiotics and treatment times. Antibiotic
prescriptions can be encouraged or discouraged via the
use of PCT serum levels. The clinical course of pneumonia is
reflected in the serum levels of PCT and CRP. CRP is
already a widely used biomarker during the follow-up of
infectious processes, and it is included in the clinical
protocols of several hospitals. Decreasing the levels of these
biomarkers is critical to predicting patient survival, and
increased biomarker levels indicate the progression to septic
shock, multiple organ failure and death. New biomarkers,
such as pro-ANP and copeptin, are under investigation, and
these markers demonstrate effective prognostic powers.
Finally, PCT is currently the most appropriate biomarker.
PCT distinguishes cases according to their severity, and the
PCT levels may direct the treatment of complicated cases.
PCT levels rise in proportion to the severity of the bacterial
infection, but the levels do not increase in viral infections.
Therefore, low PCT levels preclude the need for antibiotics.
Elevated PCT levels are associated with an increased rate of
bacteremia, septic shock, multi-organ failure and mortality.
Decreasing PCT levels during antimicrobial treatment
indicate a favorable outcome with a lowered risk of death.
The behavior of infections remains unclear. Biomarkers
may assist clinicians in determining the severity of the
patient symptoms in these diseases.
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